The story is upbeat and hopeful. If one reads 100 stockholders reports of biotech firms, one can read a lot of upbeat and hopeful stories. That makes it hard to get too excited about one more, until a vaccine is shown to be successful in phase III tests.

This article was extremely informative and wellwritten. It felt good to read it.

Influenza 101; as the flu genetic structure is explained in terms a high school science student can comprehend, however therein lies its flaw. The lack of clinical trial data or sufficient evidence of effectiveness renders this piece silver bullet speculation.

This is good, standard, scientific journalism, written for a reader with a greater than average education. It states the problem, the solution, and the possible problems with the solution. My only quibble, and that's more style than substance, is the lede is a non sequitur. I want it here and now, without the nonsense of the pseudointellectual lede. But that's the in style now. Sigh! I would have liked more background about influenza A, but it probably would be longer than the word limit. Another loss in these short, targetted articles.

A well written article about the process and possible development of a vaccine.